Cargando…
Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy
Interleukin-15 (IL-15) can promote both innate and adaptive immune reactions by stimulating CD8(+)/CD4(+) T cells and natural killer cells (NK) while showing no effect in activating T-regulatory (Treg) cells or inducing activation-associated death among effector T cells and NK cells. Thus, IL-15 is...
Autores principales: | Hu, Qiyue, Ye, Xin, Qu, Xiangdong, Cui, Dongbing, Zhang, Lei, Xu, Zhibin, Wan, Hong, Zhang, Lianshan, Tao, Weikang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955975/ https://www.ncbi.nlm.nih.gov/pubmed/29769573 http://dx.doi.org/10.1038/s41598-018-25987-4 |
Ejemplares similares
-
Discovery of SHR9352: A Highly Potent G Protein-Biased μ-Opioid
Receptor Agonist
por: Li, Xin, et al.
Publicado: (2017) -
Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis
por: Liu, Suxing, et al.
Publicado: (2021) -
IL-15 in the Combination Immunotherapy of Cancer
por: Waldmann, Thomas A., et al.
Publicado: (2020) -
Heterodimeric IL-15 in Cancer Immunotherapy
por: Bergamaschi, Cristina, et al.
Publicado: (2021) -
Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy
por: Zhang, Ying, et al.
Publicado: (2022)